Get started
Author

Madison J. Davis

Observed names: M.J. Davis, Madison Davis, Madison J Davis
ORCID: 0000-0002-1293-8974
Observed ORCID: 0000-0002-1293-8974
OpenAlex ID: A5043113298
Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy
2021 · Stephen L. Shiao, Kathleen M. Kershaw, et al. · Cancer Cell · 283
Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer
2024 · Stephen L. Shiao, Kenneth H. Gouin, et al. · Cancer Cell · 212
PDF
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
2019 · Richard Tuli, Stephen L Shiao, et al. · EBioMedicine · 121
PDF
Arginase Is Essential for Survival of Leishmania donovani Promastigotes but Not Intracellular Amastigotes
2016 · Jan M. Boitz, Caslin A. Gilroy, et al. · Infection and Immunity · 81
PDF
TAMH: A Useful In Vitro Model for Assessing Hepatotoxic Mechanisms
2016 · Madison Davis, Brendan D. Stamper · BioMed Research International · 16
PDF
Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2023 · Michael D. Jain, David B. Miklos, et al. · Clinical Cancer Research · 9
PDF
Exploring the Amino Acid Residue Requirements of the RNA Polymerase (RNAP) α Subunit C-Terminal Domain for Productive Interaction between Spx and RNAP of Bacillus subtilis
2017 · Cierra A. Birch, Madison J. Davis, et al. · Journal of Bacteriology · 9
Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma
2025 · Soumya Poddar, Jiali Yan, et al. · Journal of Clinical Investigation · 5
PDF
Model-based Evaluation of Gene Expression Changes in Response to Leishmania Infection
2019 · Brendan D Stamper, Madison Davis, et al. · Gene Regulation and Systems Biology · 5
252 Pre-treatment IL-15 serum levels correlate with the incidence and severity of neurological events following the administration of anti-CD19 CAR-T cells
2024 · Madison J Davis, Justin Budka, et al. · Journal for ImmunoTherapy of Cancer · 1
Ctim-37. a Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/refractory Primary and Secondary Central Nervous System Lymphoma (pcnsl and Scnsl)
2023 · Lakshmi Nayak, Caroline Falvey, et al. · Neuro-Oncology · 1
PDF
Overcoming Chemoresistance in Pancreatic Cancer by Targeting the Anti‐Apoptotic Mcl‐1 Protein
2016 · Adeleke Badejo, Jordan McCreary, et al. · The FASEB Journal · 1
Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma
2026 · Justin Budka, Madison Davis, et al. · Nature Medicine
PDF
Supplementary Methods S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S7 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Table S2 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S6 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Table S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S3 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S2 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S8 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S5 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S4 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel
2024 · Soumya Poddar, Jiali Yan, et al. · Blood
PDF
Works count: 59
Citation count: 744
H-index: 7
I10-index: 5
Year
Topic
Type